The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Tonmoy Sharma, once a high-profile doctor in the UK, has long courted headlines- first for his research work and then for the ...

Court filings give insight into why shooting suspect Louis Mangione might have targeted the UnitedHealthcare executive: "It checks every box." In other news: Hospital construction trends include AI; ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Now, let's return to our question: Should you invest $1,000 in Lilly right now? The shares are trading for 34 times forward ...

It sounds like the tail end of a pharmaceutical commercial: "A month's supply of insulin could cost as little as $35." But that's the deal New Mexico Attorney General Raúl Torrez is poised to maintain ...

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, is undergoing a significant transformation in ...

As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...